Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 versus Placebo in Levodopa-induced Dyskinesia in Parkinson's Disease

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 versus Placebo in Levodopa-induced Dyskinesia in Parkinson's Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Befiradol (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Adverse reactions; Proof of concept
  • Sponsors Neurolixis
  • Most Recent Events

    • 15 Jan 2024 According to a Neurolixis media release, results of this study were discussed in a new interview between Arthur Roach, director of Parkinson's UK Virtual Biotech, and Adrian Newman-Tancredi, CEO of Neurolixis.
    • 27 Jun 2023 According to a Neurolixis media release, this study was supported by Parkinson's UK (grant DYS-20-02) and The Michael J. Fox Foundation (grant MJFF- 019508).
    • 27 Jun 2023 According to a Neurolixis media release, detailed results from this trial will be presented at the forthcoming World Parkinson's Congress (WPC) 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top